| Literature DB >> 23928650 |
Daniela Dobre1, Jeffrey S Borer, Kim Fox, Karl Swedberg, Kirkwood F Adams, John G F Cleland, Alain Cohen-Solal, Mihai Gheorghiade, Francois Gueyffier, Christopher M O'Connor, Mona Fiuzat, Athul Patak, Ileana L Piña, Giuseppe Rosano, Hani N Sabbah, Luigi Tavazzi, Faiez Zannad.
Abstract
Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (risk factor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bradycardic agent. First published online by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.Entities:
Keywords: Amiodarone; Beta‐blockers; Chronic heart failure; Digoxin; Heart rate; Heart rate‐lowering drugs; Ivabradine; Verapamil
Mesh：
Substances：
Year: 2013 PMID： 23928650 DOI： 10.1093/eurjhf/hft129
Source DB: PubMed Journal: Eur J Heart Fail ISSN： 1388-9842 Impact factor: 15.534